APVO Intrinsic Valuation and Fundamental Analysis - Aptevo Therapeutics Inc

	Aptevo Therapeutics Inc NASDAQ:APVO	US
	Black Hills Corp NYSE:BKH	US
	Technical Publications Service SpA MIL:TPS	IT
C	Chow Tai Fook Jewellery Group Ltd XMUN:1CT	HK

Intrinsic Value

APVO doesn't have a meaningful market cap.

Is APVO undervalued or overvalued?

See the intrinsic value estimate for Aptevo Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.

Do our valuations actually work? See backtest results .

APVO Intrinsic Value

Unlock

Today vs. history

See how today’s valuation compares with APVO’s past valuations and how the stock performed after similar periods.

See what happened next Free account required

Track Buy Zone

20% below Intrinsic Value

Get notified when the price drops into your buy zone

Intrinsic Value Locked

Margin of Safety 20% Locked

Current Price $1.36

Or choose another margin of safety

0% below Intrinsic Value

10% below Intrinsic Value

30% below Intrinsic Value

40% below Intrinsic Value

50% below Intrinsic Value

Custom

Fundamental Analysis

What Aptevo Therapeutics Does

Biotechnology Health Care

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 33 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine.

Headquarters: United States of America US
Employees: 33
IPO date: Jul 20, 2016